Develops blood-based genomic screening services for disease risk assessment.
Jun 2026Revenue $3.13M/yrExpenses $5.68M/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will BioNexus Gene Lab be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $3.13M and expenses $5.68M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $7.42M | $10.4M | −$2.97M |
| Dec 2024 | $9.51M | $11.1M | −$1.57M |
| Dec 2023 | $9.77M | $12.4M | −$2.59M |
| Dec 2022 | $10.9M | $11.2M | −$291K |
| Dec 2021 | $13.4M | $12.3M | $1.06M |
| Dec 2020 | $11.4M | $10.1M | $1.27M |
| Dec 2019 | $127K | $403K | −$276K |
| Dec 2018 | $212K | $152K | $59.9K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.